08:30 AM EDT, 06/10/2025 (MT Newswires) -- Profound Medical ( PROF ) on Tuesday said the first commercial treatment using the new Tulsa-AI volume reduction module in conjunction with the Tulsa-Pro system, was performed on Monday.

The procedure was performed on a patient with benign prostatic hyperplasia, or BPH, a non-cancerous enlargement of the prostate gland. It is a common condition as men age and creates significant lower urinary tract symptoms. Current BPH treatment, which has been largely unchanged over the past 100 years, can cause significant morbidity, a statement said.

Profound Medical ( PROF ) said the Tulsa-AI procedure for BPJ patients can be completed within 90 minutes, with minimal complications and no overnight stay, making the treatment option more accessible for many more BPH-only patients.

"Accordingly, we believe that TULSA-AI will expand our total, truly tangible available market opportunity from 200,000 to 600,000 prostate disease patients per year," said Arun Menawat, chief executive officer.